Scholarlink

<p>Alkylating agent-based chemotherapy is one of the main treatment options for patients with metastatic pancreatic neuroendocrine tumors (PanNETs).However, it favors the acquisition of a hypermutator phenotype, suggesting a potential benefit of immunotherapy.</p><p>We aimed to describe the efficacy of immunotherapy in an international retrospective cohort of patients with metastatic well-differentiated PanNETs pretreated with alkylating therapy. The primary endpoint was progression-free survival (PFS) and the main secondary endpoint was the radiological objective response rate (ORR). We explored the impact of tumor mutation burden (TMB) and mismatch repair deficiency (MMRd), and evaluated variables associated with PFS.</p><p>We included 64 patients with heavily pretreated PanNETs (median Ki-67 28%). Among 51 PanNETs with mutational profiling, 37 (73%) were TMB<sup>high</sup> (median 35 mut/Mb). Among 46 PanNETs with available MMR status, 18 (39%) were MMRd, representing 49% of all TMB<sup>high</sup> PanNETs. Immunotherapy consisted of a single (31%) or a dual (69%) immune checkpoint inhibitor. Median PFS was 3.2 months (95% CI, 1.3–5.0.3.0) and the ORR was 17%. Patients with TMB<sup>high</sup> PanNETs had longer PFS (median 3.8 vs. 2.3 months, <i>p</i> = 0.015) and higher ORR (30% vs. 0%, <i>p</i> = 0.002) compared with TMB<sup>low/unk</sup> cases. Patients with MMRd PanNETs had longer PFS (median 8.9 vs. 2.7 months, <i>p</i> = 0.003) and higher ORR (44% vs. 7%, <i>p</i> &lt; 0.001) compared with MMRp/unk. On multivariable analyses, MMRd predicted longer PFS (HR 0.42, 95% CI [0.20–0.82], <i>p</i> = 0.015).</p><p>Overall, immunotherapy may be effective against alkylating-pretreated metastatic PanNETs exhibiting TMB<sup>high</sup> and MMRd. MMR immunohistochemistry and TMB assessment could be implemented in the routine assessment of alkylating-pretreated metastatic PanNETs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy

  • 期刊论文

  • 发表日期：

    2025年11月3日

查看全文
  • Louis de Mestier,
  • Thorvardur R. Halfdanarson,
  • Leonidas Apostolidis,
  • Anna Koumarianou,
  • Jorge Hernando,
  • Rachel Riechelmann,
  • Emily K. Bergsland,
  • Sara Cingarlini,
  • Shagufta Shaheen,
  • Joakim Crona,
  • Simon Kreutzfeldt,
  • Osama Mosalem,
  • Taymeyah Al-Toubah,
  • Jérôme Cros,
  • Jonathan R. Strosberg

摘要

Alkylating agent-based chemotherapy is one of the main treatment options for patients with metastatic pancreatic neuroendocrine tumors (PanNETs).However, it favors the acquisition of a hypermutator phenotype, suggesting a potential benefit of immunotherapy.

We aimed to describe the efficacy of immunotherapy in an international retrospective cohort of patients with metastatic well-differentiated PanNETs pretreated with alkylating therapy. The primary endpoint was progression-free survival (PFS) and the main secondary endpoint was the radiological objective response rate (ORR). We explored the impact of tumor mutation burden (TMB) and mismatch repair deficiency (MMRd), and evaluated variables associated with PFS.

We included 64 patients with heavily pretreated PanNETs (median Ki-67 28%). Among 51 PanNETs with mutational profiling, 37 (73%) were TMBhigh (median 35 mut/Mb). Among 46 PanNETs with available MMR status, 18 (39%) were MMRd, representing 49% of all TMBhigh PanNETs. Immunotherapy consisted of a single (31%) or a dual (69%) immune checkpoint inhibitor. Median PFS was 3.2 months (95% CI, 1.3–5.0.3.0) and the ORR was 17%. Patients with TMBhigh PanNETs had longer PFS (median 3.8 vs. 2.3 months, p = 0.015) and higher ORR (30% vs. 0%, p = 0.002) compared with TMBlow/unk cases. Patients with MMRd PanNETs had longer PFS (median 8.9 vs. 2.7 months, p = 0.003) and higher ORR (44% vs. 7%, p < 0.001) compared with MMRp/unk. On multivariable analyses, MMRd predicted longer PFS (HR 0.42, 95% CI [0.20–0.82], p = 0.015).

Overall, immunotherapy may be effective against alkylating-pretreated metastatic PanNETs exhibiting TMBhigh and MMRd. MMR immunohistochemistry and TMB assessment could be implemented in the routine assessment of alkylating-pretreated metastatic PanNETs.